Scribe Therapeutics Closes $155.5 Million IPO, Secures Sanofi Private Placement

Scribe Therapeutics Inc. (Nasdaq: SCTX) has successfully closed its initial public offering, raising aggregate gross proceeds of approximately $155.51 million before underwriting discounts and commissions. The offering's completion marks a significant capital infusion for the clinical-stage biotechnology company as it advances its development pipeline.

Offering Details

The Alameda, California-based company sold a total of 9,867,000 shares of its common stock at an IPO price of $15.00 per share. This figure includes 1,287,000 additional shares sold after the underwriters fully exercised their option to purchase more, according to a company press release.

The offering was managed by a syndicate of banks, with Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities, and Wells Fargo Securities acting as joint book-running managers. The company's registration statement was declared effective by the U.S. Securities and Exchange Commission on July 23, 2026.

Concurrent Sanofi Investment

Ad

Alongside the public offering, Scribe Therapeutics also closed a concurrent private placement with the pharmaceutical company Sanofi. Sanofi purchased 500,000 shares of common stock at the IPO price of $15.00 per share.

These shares were not registered under the Securities Act of 1933 and are therefore subject to different regulations than those sold in the public offering. This separate transaction underscores existing investor interest from established industry players.

Market Debut

Shares of Scribe Therapeutics began trading on the Nasdaq Global Market on July 24, 2026, under the ticker symbol SCTX. The initial public offering officially closed on July 27, 2026, finalizing the process and securing the new capital for the company's operations.